tetraethyleneglycol dimethacrylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tetraethyleneglycol dimethacrylate: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	7980
CHEMBL ID	3184138
SCHEMBL ID	15895
MeSH ID	M0259379

Synonyms (54)

Synonym
25101-32-0
sr 209
3,6,9-trioxaundecamethylene dimethacrylate
nsc 84253
brn 1803537
einecs 203-653-1
tgm 4
ccris 3435
2-propenoic acid, 2-methyl-, oxybis(2,1-ethanediyloxy-2,1-ethanediyl) ester
te egdma
tetraethylene glycol, dimethacrylate
tetraethyleneglycol dimethacrylate
methacrylic acid, oxybis(ethyleneoxyethylene) ester
tgm-4
109-17-1
nsc-84253
nsc84253
methacrylic acid, diester with tetraethylene glycol
tetraethylene glycol dimethacrylate
tetraethylene glycol dimethacrylate, technical, >=90% (gc)
2-[2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethoxy]ethyl 2-methylprop-2-enoate
NCGC00248228-01
2-propenoic acid, 2-methyl-, 1,1'-(oxybis(2,1-ethanediyloxy-2,1-ethanediyl)) ester
ct038eqf54 ,
unii-ct038eqf54
cas-109-17-1
dtxcid4024515
dtxsid6044515 ,
NCGC00254858-01
tox21_300956
((oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl) bis(2-methylacrylate)
transglutaminase 5
peg-4 dimethacrylate
peg-4 dimethacrylate [inci]
T3486
SCHEMBL15895
LTHJXDSHSVNJKG-UHFFFAOYSA-N
14-methyl-13-oxo-3,6,9,12-tetraoxapentadec-14-en-1-yl 2-methylacrylate #
CHEMBL3184138
tetraethylene glycol dimethacrylate(7 cp(25 degrees c))
J-002240
tetraethylene glycol dimethacrylate, contains <=1500 ppm mehq as inhibitor, 95%
mfcd00014932
mfcd00081877
tetraethylene glycol dimethacrylate, contains ~0.006% hydroquinone as stabilizer, 90%
tetraethylene glycol dimethacrylate (stabilized with hq)
F20349
tetraethylene glycol dimethacrylate; tegdma
Q27275744
D84708
((oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl)bis(2-methylacrylate)
tetraethyleneglycoldimethacrylate
BS-44110
peg bismethacrylate

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
GLI family zinc finger 3	Homo sapiens (human)	Potency	15.3553	0.0007	14.5928	83.7951	AID1259392
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	52.9589	0.0010	22.6508	76.6163	AID1224838; AID1224893
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	56.6363	0.0391	47.5451	146.8240	AID1224845
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	32.9384	0.0006	27.2152	1,122.0200	AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (5.26)	18.2507
2000's	11 (28.95)	29.6817
2010's	23 (60.53)	24.3611
2020's	2 (5.26)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	22.09 (24.57)
Research Supply Index	3.71 (2.92)
Research Growth Index	5.28 (4.65)
Search Engine Demand Index	31.58 (26.88)
Search Engine Supply Index	3.00 (0.95)

This Compound (22.09)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	4 (10.00%)	6.00%
Case Studies	9 (22.50%)	4.05%
Observational	0 (0.00%)	0.25%
Other	27 (67.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
acetone methyl ketone : A ketone of formula RC(=O)CH3 (R =/= H).	2.1	1	ketone body; methyl ketone; propanones; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; human metabolite; polar aprotic solvent
mercaptoethanol Mercaptoethanol: A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation.	2.1	1	alkanethiol; primary alcohol	geroprotector
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	2.04	1	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
azobis(isobutyronitrile) azobis(isobutyronitrile): blowing agent for elastomers & plastics; initiator for free radical reactions; structure	2.1	1
methylethyl ketone methylethyl ketone: solvent; colorless synthetic resins, smokeless powders; may be irritating to eyes, mucous membranes; may be toxic in high concentrations; structure. butanone : Any ketone that is butane substituted by an oxo group at unspecified position.. butan-2-one : A dialkyl ketone that is a four-carbon ketone carrying a single keto- group at position C-2.	2.1	1	butanone; dialkyl ketone; methyl ketone; volatile organic compound	bacterial metabolite; polar aprotic solvent
methylmethacrylate Methylmethacrylate: The methyl ester of methacrylic acid. It polymerizes easily to form POLYMETHYL METHACRYLATE. It is used as a bone cement.. methyl methacrylate : An enoate ester having methacrylic acid as the carboxylic acid component and methanol as the alcohol component.	2.05	1	enoate ester; methyl ester	allergen; polymerisation monomer
allyl methacrylate [no description available]	2.05	1
ethylene dimethacrylate ethylene glycol dimethacrylate : The enoate ester that is the 1,2-bis(methacryloyl) derivative of ethylene glycol.	2.48	2	enoate ester	allergen; cross-linking reagent; polymerisation monomer
2-ethylhexyl acrylate [no description available]	2.05	1	enoate ester
triethylene glycol dimethacrylate [no description available]	2.72	3
ethyl acrylate [no description available]	2.05	1	enoate ester
n-butyl acrylate butyl acrylate : An acrylate ester obtained by the formal condensation of the hydroxy group of butan-1-ol with the carboxy group of acrylic acid.	2.05	1	acrylate ester
hydroxyethyl methacrylate hydroxyethyl methacrylate: many of cited refs are for gel which refers to polymeric form of above cpd: POLYHYDROXYETHYL METHACRYLATE. 2-hydroxyethyl methacrylate : An enoate ester that is the monomethacryloyl derivative of ethylene glycol.	2.47	2	enoate ester	allergen; polymerisation monomer
bisphenol a-glycidyl methacrylate Bisphenol A-Glycidyl Methacrylate: The reaction product of bisphenol A and glycidyl methacrylate that undergoes polymerization when exposed to ultraviolet light or mixed with a catalyst. It is used as a bond implant material and as the resin component of dental sealants and composite restorative materials.	2.93	4	diarylmethane
benzyl methacrylate [no description available]	2.05	1
hexyl acrylate [no description available]	2.05	1
2-(dimethylamino)ethyl methacrylate 2-(dimethylamino)ethyl methacrylate: reducing agent; structure given in first source	1.99	1
camphoroquinone camphoroquinone: a natural monoterpene, non-aromatic quinone; structure given in first source. bornane-2,3-dione : A bornane monoterpenoid that is bicyclo[2.2.1]heptane substituted by methyl groups at positions 1, 7 and 7 and oxo groups at positions 2 and 3.	1.99	1	bornane monoterpenoid; carbobicyclic compound
2-isocyanatoethyl methacrylate 2-isocyanatoethyl methacrylate: used in coating materials	2.1	1
1,10-decanediol [no description available]	2.11	1
2,2-bis-(4-(2-methacryloxyethoxy)phenyl)propane 2,2-bis-(4-(2-methacryloxyethoxy)phenyl)propane: structure given in first source	2.1	1
cyanates Cyanates: Organic salts of cyanic acid containing the -OCN radical.. cyanates : Salts and esters of cyanic acid, HOC#N; compounds carrying the cyanate functional group -O-C#N.. isocyanates : Organonitrogen compounds that are derivatives of isocyanic acid; compounds containing the isocyanate functional group -N=C=O (as opposed to the cyanate group, -O-C#N).	2.1	1
1,12-dodecanediol dimethacrylate 1,12-dodecanediol dimethacrylate: structure in first source	1.98	1
cannabidiol Cannabidiol: Compound isolated from Cannabis sativa extract.. cannabidiol : An cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4.	2.08	1	olefinic compound; phytocannabinoid; resorcinols	antimicrobial agent; plant metabolite
anandamide anandamide : An N-acylethanolamine 20:4 resulting from the formal condensation of carboxy group of arachidonic acid with the amino group of ethanolamine.	2.04	1	endocannabinoid; N-acylethanolamine 20:4	human blood serum metabolite; neurotransmitter; vasodilator agent
cannabigerol cannabigerol: RN given refers to (E)-isomer; structure given in first source. cannabigerol : A member of the class of resorcinols that is resorcinol which is substituted by a (2E)-3,7-dimethylocta-2,6-dien-1-yl group at position 2 and by a pentyl group at position 5. It is a natural product found in Cannabis sativa and Helichrysum species.	2.08	1	phytocannabinoid; resorcinols	anti-inflammatory agent; antibacterial agent; antioxidant; appetite enhancer; cannabinoid receptor agonist; neuroprotective agent; plant metabolite
involucrin involucrin: soluble precursor protein of cross-linked envelope characteristic of epidermal s. corneum synthesized by keratinocytes in natural & cultured human epithelia; see also related records for prekeratin & stratum corneum basic protein precursor	2.97	4
cannabidivarin cannabidivarin: from Cannabis sativa	2.08	1	monoterpenoid
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	2.42	2	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor

Condition	Relationship Strength	Studies
Autosomal Dominant Cerebellar Ataxia, Type II [description not available]	2.41	1
Spinocerebellar Ataxias A group of predominately late-onset, cerebellar ataxias which have been divided into multiple subtypes based on clinical features and genetic mapping. Progressive ataxia is a central feature of these conditions, and in certain subtypes POLYNEUROPATHY; DYSARTHRIA; visual loss; and other disorders may develop. (From Joynt, Clinical Neurology, 1997, Ch65, pp 12-17; J Neuropathol Exp Neurol 1998 Jun;57(6):531-43)	2.41	1
Collodion Baby Syndrome [description not available]	2.25	1
Dermatitis Exfoliativa [description not available]	4.4	7
Genetic Skin Diseases [description not available]	2.25	1
Hand Dermatosis [description not available]	3.5	2
Foot Dermatoses Skin diseases of the foot, general or unspecified.	3.5	2
Dermatitis, Exfoliative The widespread involvement of the skin by a scaly, erythematous dermatitis occurring either as a secondary or reactive process to an underlying cutaneous disorder (e.g., atopic dermatitis, psoriasis, etc.), or as a primary or idiopathic disease. It is often associated with the loss of hair and nails, hyperkeratosis of the palms and soles, and pruritus. (From Dorland, 27th ed)	4.4	7
Hand Dermatoses Skin diseases involving the HANDS.	3.5	2
Ichthyosis, Lamellar A chronic, congenital ichthyosis inherited as an autosomal recessive trait. Infants are usually born encased in a collodion membrane which sheds within a few weeks. Scaling is generalized and marked with grayish-brown quadrilateral scales, adherent at their centers and free at the edges. In some cases, scales are so thick that they resemble armored plate.	2.25	1
Dermatoses [description not available]	5.41	13
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	5.41	13
Dementia Praecox [description not available]	2.55	2
Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.	2.55	2
Celiac Sprue [description not available]	3.09	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.09	1
Duhring Disease [description not available]	3.09	1
Celiac Disease A malabsorption syndrome that is precipitated by the ingestion of foods containing GLUTEN, such as wheat, rye, and barley. It is characterized by INFLAMMATION of the SMALL INTESTINE, loss of MICROVILLI structure, failed INTESTINAL ABSORPTION, and MALNUTRITION.	3.09	1
Dermatitis Herpetiformis Rare, chronic, papulo-vesicular disease characterized by an intensely pruritic eruption consisting of various combinations of symmetrical, erythematous, papular, vesicular, or bullous lesions. The disease is strongly associated with the presence of HLA-B8 and HLA-DR3 antigens. A variety of different autoantibodies has been detected in small numbers in patients with dermatitis herpetiformis.	3.09	1
Acantholysis Bullosa [description not available]	2.5	2
Epidermolysis Bullosa Group of genetically determined disorders characterized by the blistering of skin and mucosae. There are four major forms: acquired, simple, junctional, and dystrophic. Each of the latter three has several varieties.	2.5	2
Incontinentia Pigmenti Achromians [description not available]	4.25	6
EBS-DM [description not available]	2.1	1
Epidermolysis Bullosa Simplex A form of epidermolysis bullosa characterized by serous bullae that heal without scarring. Mutations in the genes that encode KERATIN-5 and KERATIN-14 have been associated with several subtypes of epidermolysis bullosa simplex.	2.1	1
Hyperidrosis [description not available]	2.1	1
Hyperhidrosis Excessive sweating. In the localized type, the most frequent sites are the palms, soles, axillae, inguinal folds, and the perineal area. Its chief cause is thought to be emotional. Generalized hyperhidrosis may be induced by a hot, humid environment, by fever, or by vigorous exercise.	2.1	1
Congenital Limb Deformities [description not available]	3.03	1
Anodontia Congenital absence of the teeth; it may involve all (total anodontia) or only some of the teeth (partial anodontia, hypodontia), and both the deciduous and the permanent dentition, or only teeth of the permanent dentition. (Dorland, 27th ed)	3.03	1
Nail Abnormalities [description not available]	3.03	1
Anhidrotic Ectodermal Dysplasia [description not available]	3.03	1
Lacrimal Duct Obstruction Interference with the secretion of tears by the lacrimal glands. Obstruction of the LACRIMAL SAC or NASOLACRIMAL DUCT causing acute or chronic inflammation of the lacrimal sac (DACRYOCYSTITIS). It is caused also in infants by failure of the nasolacrimal duct to open into the inferior meatus and occurs about the third week of life. In adults occlusion may occur spontaneously or after injury or nasal disease. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p250)	3.03	1
Genetic Predisposition [description not available]	2.77	3
Psychoses [description not available]	2.13	1
Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)	2.13	1
Symptom Cluster [description not available]	4.06	5
Syndrome A characteristic symptom complex.	4.06	5
Bleb [description not available]	2.05	1
Erythema Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.	2.05	1
Skin Aging The process of aging due to changes in the structure and elasticity of the skin over time. It may be a part of physiological aging or it may be due to the effects of ultraviolet radiation, usually through exposure to sunlight.	2.05	1
Xeroderma [description not available]	2.97	1
Ichthyosis Any of several generalized skin disorders characterized by dryness, roughness, and scaliness, due to hypertrophy of the stratum corneum epidermis. Most are genetic, but some are acquired, developing in association with other systemic disease or genetic syndrome.	2.97	1
Hypoproteinemia A condition in which total serum protein level is below the normal range. Hypoproteinemia can be caused by protein malabsorption in the gastrointestinal tract, EDEMA, or PROTEINURIA.	2.05	1
Bullous Congenital Ichthyosiform Erythroderma [description not available]	2.43	2
Bullous Dermatoses [description not available]	2.07	1
Eczema, Atopic [description not available]	2.07	1
Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.	2.07	1
Palmoplantaris Pustulosis [description not available]	2.01	1
Ichthyosis Simplex [description not available]	2.01	1
Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	2.01	1

chemdatabank.com